Information Provided By: 
Fly News Breaks for June 14, 2018
MYL
Jun 14, 2018 | 07:02 EDT
RBC Capital analyst Randall Stanicky kept his $42 price target and Sector Perform rating on Mylan following yesterday's FDA delay of generic Advair due to "minor deficiencies". The analyst notes that the company may be faced with worse than expressed business pressure and is also concerned that the Street may have over-modeled the Advair contribution, warning that the stock price may pull back through Q2. Stanicky says investors should await a better entry point opportunity on Mylan.
News For MYL From the Last 2 Days
There are no results for your query MYL
